While most observers are waiting to see whether GSK plc and Pfizer Inc.'s respective respiratory syncytial virus (RSV) vaccines will secure US approval next month, Bavarian Nordic A/S is catching up with its offering which could challenge the big pharma players in this hot space.
The Danish company, which has seen sales soar after its smallpox vaccine Jynneos became a critical tool in the global...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)